Close 2026-08-21 1267 scanned A

ARTEMISMED

Artemis Medicare Services
Mid capRs 5,162 crRs 14.3 cr traded a day
Close on 2026-08-21
326.10
+1.49%
52-week range100% of the way up
205.51326.10
Market cap
5,162 cr
P/E (TTM)
45.3×
EPS (TTM)
7.20
Revenue YoY
+12.7%
Q1 FY27
Profit YoY
+48.3%
Net margin
10.9%
+2.6pt vs a year ago
Growth trend
-3.7pt
vs last quarter’s YoY
1 month
+20.0%
Below 52w high
0.0%
RSI (14)
69
Daily swing
3.7%
average true range
Volume
1.7×
vs 20-day average
Traded
Rs 14 cr
median day
Close200-day averageMaterial filing
200250300Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
+3.61%
1 month
+19.96%
3 months
+14.97%
6 months
+38.86%
1 year
+45.04%

The read

written from the numbers on this page
The evidence leans constructive7 supporting, 0 against, 0 worth knowing

Supporting

  • trading 26% above its 200-day average
  • sitting at 100% of its 52-week range, with little overhead supply from trapped buyers
  • up 45% over twelve months
  • matches made a new 52-week high today, which has beaten the market by +1.03 points over 20 sessions across 9,118 past signals
  • 3 of the scans it matches have a positive measured record
  • 5 independent kinds of evidence agree today, which is uncommon
  • revenue grew 13% year on year in the quarter ending 2026-06-30

Against

  • nothing the data supports either way

Worth knowing

  • nothing the data supports either way
What would change this read: a close below 260, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

read from the filings, with the figure behind every line
Working3

Net profit +48.3% year on year, Rs 21 cr to Rs 31 cr.

+48.3%Rs 21 crRs 31 cr

Profit rose year on year in all 4 of the last 4 quarters.

4

Profit grew faster than revenue, +48.3% against +12.7%.

+48.3%+12.7%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.

How it has performed

price return over each window, measured against zero
+3.6%1W+20.0%1M+15.0%3M+38.9%6M+45.0%1Y

What the scans say today

10 of 47 matched on 2026-08-21
ARTEMISMED matches 10 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Valuation against its own history

500 sessions since 2024-09-06
38×
median 46×
81×
now 45×
ARTEMISMED trades at 45× trailing earnings, close to its median of 46× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
08-10
13:43
Analyst call
1d-0.15d+0.320d
08-04
15:19
Analyst call
1d-0.15d+4.620d
08-04
12:31
Other filing
1d-0.15d+4.620d
08-03
18:28
Other filing
1d-0.15d+4.620d
08-03
17:54
Other filing
1d-0.15d+4.620d
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
2412322402552752722792879.2%8.2%10.9%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 13% against the same quarter a year earlier
  • profit rose 48% year on year
  • net margin widened from 10.8% to 10.9%
  • revenue rose in 3 of the last 4 quarters

Going against it

  • nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
28743311.9810.9%
Q4 FY26
2026-03-31 · consolidated
27940301.9010.8%
Q3 FY26
2025-12-31 · consolidated
27230221.418.2%
Q2 FY26
2025-09-30 · consolidated
27539301.9010.9%
Q1 FY26
2025-06-30 · consolidated
25530211.358.3%
Q4 FY25
2025-03-31 · consolidated
24029231.479.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+14.7%
Versus 200-day average+25.6%
Below 52-week high+0.0%
Above 52-week low+58.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)68.9
Higher closes in last 53 of 5
Six-month return+38.86%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.68%
Volume versus 20-day1.7x
Median daily turnoverRs 14.3 cr

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
2026-08-211Closing in on a 52-week high